BAJAJ BROKING
The Competition Commission of India has approved the merger of Aster DM Healthcare and Quality Care India Ltd. The new entity, Aster DM Quality Care Ltd, will operate 38 hospitals with over 10,150 beds across 27 cities in India.
The Competition Commission of India (CCI) has approved the merger of Aster DM Healthcare Ltd and Quality Care India Ltd (QCIL) through a scheme of amalgamation. The merged entity will be named Aster DM Quality Care Ltd, creating one of India's largest private healthcare networks.
Also read: ICICI Lombard Q4 Profit Falls 1.9%, Declares ₹7 Final Dividend
Aster DM Healthcare and QCIL to merge, forming Aster DM Quality Care Ltd.
Combined entity to operate 38 hospitals with over 10,150 beds across 27 cities.
Aster to acquire a 5% stake in QCIL from BCP Asia and Centella before the merger.
Post-merger, Aster shareholders will hold 57.3%, and QCIL shareholders 42.7% in the new entity.
Aster DM Healthcare share price closed at ₹489.45 on the NSE, down 2.17% on the day of the announcement.
Also read: Oil India Wins 9 Blocks in OALP Round-IX, Acreage Jumps 85%
Prior to the merger, Aster will acquire a 5% stake in QCIL from BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Ltd in exchange for primary shares. Post-merger, Aster shareholders will hold 57.3% of the combined entity, while QCIL shareholders, including Blackstone and TPG-backed entities, will hold 42.7%. Centella will hold less than 10% stake without control rights.
The merged entity will operate 38 hospitals with over 10,150 beds across 27 cities in India. Aster currently operates 19 hospitals with 4,867 beds, 13 clinics, 215 pharmacies, and 232 labs across six states. QCIL operates 26 healthcare centres under the brands CARE Hospitals, KIMS Health, and Evercare, with over 5,150 beds in 14 cities.
For the first nine months of FY25, Aster reported a 15% revenue growth to ₹3,138 crore, with a 35% increase in operating EBITDA to ₹613 crore. The merged entity aims to expand its bed capacity by 3,500 beds over the next 2-3 years through brownfield and greenfield projects.
On the day of the announcement, Aster DM Healthcare share price closed at ₹489.45 on the NSE, down 2.17%. The share price has gained 0.21% over the last week and 1.23% since the beginning of April. Year-to-date, the stock has risen 4.77%.
The merger of Aster DM Healthcare and Quality Care India Ltd marks a significant consolidation in India's private healthcare sector. The combined entity, Aster DM Quality Care Ltd, will have a substantial presence across the country, offering a wide range of medical services and specialties. Investors and stakeholders will closely monitor the integration process and the performance of the merged entity in the coming quarters.
Also read: IndusInd Bank Finds ₹1,979 Crore Net Worth Hit in Derivatives Audit
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading